Objective: To perform a systematic review of therapeutic agents for the prevention and treatment of oral mucositis in head and neck cancer patients undergoing chemo-radiotherapy (CRT) or radiotherapy (RT). Methods: Electronic search via MEDLINE, EMBASE, and Cochrane Central Register of Controlled ...
The administration of many chemo-radiotherapy regimens in patients with cancer may be complicated by toxicities that limit the clinicians' abilities to deliver the most effective doses of active agents. Oral mucositis is a major dose-limiting toxic effect and the most important cause of morbidity in...
ulceration, or combinations thereof, affecting the gastrointestinal tract from the mouth to anus, which results from disease or is secondary to therapeutic treatments such as certain chemotherapies, ionizing radiation, or combinations thereof, or is secondary to any mucositis-inducing circumstance or ev...
It has been found that these compositions and methods effectively alleviate mucositis in susceptible individuals, especially when administered prior to, during, or after treatments commonly associated with the development of mucositis such as certain chemotherapies, radiation therapies, or combinations ...
hair loss, mouth sores, stomach upset: rapidly dividing cells in hair roots and cells that line the digestive tract may also be affected. As a result, side effects may includeloss of hair, poor appetite, nausea and vomiting, diarrhea, or mouth and lip sores (mucositis). ...
CHM offers a distinctive and comprehensive approach to manage IC, potentially enhancing patient outcomes and quality life. However, most chemo-preventative effects of these herbs have been studied in various human cancer cell lines, and to a lesser extent, in animal tumor models. Challenges such as...
approval by the US FDA in 2009, following the PROPEL phase II trial that examined the role of pralatrexate in heavily pretreated R/R PTCL. It resulted in an ORR of 29%, and the median duration of response was 10 months. The most common side effects included cytopenia and mucositis [57]...
The incidence of acute grade 3 mucositis was 24.2%. Six patients (18.2%) had grade 1 leukopenia and/or neutropenia. No grade 4 acute toxicities were observed. For the patients treated with chemoradiotherapy, seventy-six patients (46.1%) had acute grade 3 mucositis and 34 patients (20.6%) ...
Also, we look for lesions in the mouth: mucositis-like ulcers, sores. Weight loss is a very important sign when it comes to evaluating chronic GVHD. In 2014, the National Institutes of Health [NIH] standardized the way we do scoring for chronic GVHD.3 What we do now when we evaluate ...
(BMI) and diminished protein-calorie consumption before and/or during radiotherapy have been related to terrible prognosis (for example, decreased survival rate and failure of the treatment), impaired quality of life (QoL), severe mucositis and more treatment toxicity [[90], [91], [92], [93...